BioCryst Collaborates to Battle Bird Flu

March 22, 2007
BioPharm International Editors

BioCryst Pharmaceuticals, Inc. (Birmingham, AL, www.biocryst.com) and Shionogi & Co., Ltd. (Osaka, Japan, www.shionogi.co.jp) have signed an exclusive license agreement to develop and commercialize BioCryst's lead influenza neuraminidase inhibitor, peramivir, in Japan for the treatment of seasonal and potentially life-threatening human influenza.

BioCryst Pharmaceuticals, Inc. (Birmingham, AL, www.biocryst.com) and Shionogi & Co., Ltd. (Osaka, Japan, www.shionogi.co.jp) have signed an exclusive license agreement to develop and commercialize BioCryst’s lead influenza neuraminidase inhibitor, peramivir, in Japan for the treatment of seasonal and potentially life-threatening human influenza. BioCryst retains all rights to commercialize peramivir in North America, Europe, and other countries outside of Japan and Korea.